Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

High prevalence of hepatitis B virus dual infection with genotypes A and G in HIV-1 infected men in Amsterdam, the Netherlands, during 2000-2011.

van der Kuyl AC, Zorgdrager F, Hogema B, Bakker M, Jurriaans S, Back NK, Berkhout B, Zaaijer HL, Cornelissen M.

BMC Infect Dis. 2013 Nov 14;13:540. doi: 10.1186/1471-2334-13-540.

2.

Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013.

van der Kuyl AC, Bakker M, Jurriaans S, Back NK, Pasternak AO, Cornelissen M, Berkhout B.

Retrovirology. 2013 Aug 28;10:93. doi: 10.1186/1742-4690-10-93. Review.

3.

Ten years of HIV testing with fourth generation assays: the Amsterdam experience.

Jurriaans S, Back NK, Wolthers KC.

J Clin Virol. 2011 Dec;52 Suppl 1:S67-9. doi: 10.1016/j.jcv.2011.09.021. Epub 2011 Oct 12.

PMID:
21995933
4.

Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.

Cornelissen M, Back NK, Burger DM, Blom P, Portegies P, Prins JM, van der Valk M.

Antivir Ther. 2011;16(6):931-5. doi: 10.3851/IMP1781.

PMID:
21900726
5.

Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.

Hamers RL, Wensing AM, Back NK, Arcilla MS, Frissen JP.

Antivir Ther. 2011;16(1):115-8. doi: 10.3851/IMP1683.

PMID:
21311115
6.

Unusual cluster of HIV type 1 dual infections in Groningen, The Netherlands.

van der Kuyl AC, Jurriaans S, Back NK, Sprenger HG, van der Werf TS, Zorgdrager F, Berkhout B, Cornelissen M.

AIDS Res Hum Retroviruses. 2011 Apr;27(4):429-33. doi: 10.1089/aid.2010.0175. Epub 2010 Nov 18.

PMID:
21087141
7.

Multiple transmissions of a stable human leucocyte antigen-B27 cytotoxic T-cell-escape strain of HIV-1 in The Netherlands.

Cornelissen M, Hoogland FM, Back NK, Jurriaans S, Zorgdrager F, Bakker M, Brinkman K, Prins M, van der Kuyl AC.

AIDS. 2009 Jul 31;23(12):1495-500. doi: 10.1097/QAD.0b013e32832d9267.

PMID:
19487902
8.

Incidence of human immunodeficiency virus type 1 dual infections in Amsterdam, The Netherlands, during 2003-2007.

van der Kuyl AC, Zorgdrager F, Jurriaans S, Back NK, Prins JM, Brinkman K, van Eeden A, Bakker M, Cornelissen M.

Clin Infect Dis. 2009 Apr 1;48(7):973-8. doi: 10.1086/597356.

PMID:
19231977
9.

Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions.

Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NK, Jorgensen LB, de Mendoza C, Bhaskaran K, Gill ON, Johnson AM, Pillay D; Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) Collaboration.

J Infect Dis. 2009 Feb 1;199(3):427-31. doi: 10.1086/596049.

PMID:
19133810
10.

Characterization of an HIV-1 group M variant that is distinct from the known subtypes.

van der Hoek L, Pollakis G, Lukashov VV, Jebbink MF, Jeeninga RE, Bakker M, Dukers N, Jurriaans S, Paxton WA, Back NK, Berkhout B.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):466-70.

PMID:
17411380
11.

Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

Schutten M, Peters D, Back NK, Beld M, Beuselinck K, Foulongne V, Geretti AM, Pandiani L, Tiemann C, Niesters HG.

J Clin Microbiol. 2007 Jun;45(6):1712-7. Epub 2007 Apr 4.

12.

Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort.

Gali Y, Berkhout B, Vanham G, Bakker M, Back NK, Ariƫn KK.

Virology. 2007 Jul 20;364(1):140-6. Epub 2007 Mar 28.

13.

Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase.

Berkhout B, Back NK, de Ronde A, Jurriaans S, Bakker M, Parkin NT, van der Hoek L.

AIDS. 2006 Jul 13;20(11):1515-20.

PMID:
16847406
14.

Declining trend in transmission of drug-resistant HIV-1 in Amsterdam.

Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, Berkhout B, Coutinho R, Back NK.

AIDS. 2004 Jul 23;18(11):1571-7.

PMID:
15238775
15.

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.

Back NK, van Wijk A, Remmerswaal D, van Monfort M, Nijhuis M, Schuurman R, Boucher CA.

AIDS. 2000 Jan 7;14(1):101-2. No abstract available.

PMID:
10714580
16.

Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains.

Berkhout B, Verhoef K, van Wamel JL, Back NK.

J Virol. 1999 Feb;73(2):1138-45.

18.

Structural and functional analysis of negatively charged milk proteins with anti-HIV activity.

Berkhout B, Derksen GC, Back NK, Klaver B, de Kruif CG, Visser S.

AIDS Res Hum Retroviruses. 1997 Sep 1;13(13):1101-7.

PMID:
9282815
19.

Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase.

Oude Essink BB, Back NK, Berkhout B.

Nucleic Acids Res. 1997 Aug 15;25(16):3212-7.

21.

Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.

Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P, Back NK.

Antimicrob Agents Chemother. 1996 Oct;40(10):2404-9.

22.

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B.

EMBO J. 1996 Aug 1;15(15):4040-9.

23.

Development and evaluation of an HIV-1 transfection-neutralization assay.

Back NK, Smit L, Hogervorst E, van Wijk AC, Goudsmit J, Tersmette M.

J Acquir Immune Defic Syndr. 1994 Jun;7(6):531-8.

PMID:
7513760
24.

An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.

Back NK, Smit L, De Jong JJ, Keulen W, Schutten M, Goudsmit J, Tersmette M.

Virology. 1994 Mar;199(2):431-8.

PMID:
8122371
25.

Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.

Zwart G, Back NK, Ramautarsing C, Valk M, van der Hoek L, Goudsmit J.

AIDS Res Hum Retroviruses. 1994 Mar;10(3):245-51.

PMID:
8018385
26.

Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Back NK, Smit L, Schutten M, Nara PL, Tersmette M, Goudsmit J.

J Virol. 1993 Nov;67(11):6897-902.

27.

Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

Langedijk JP, Back NK, Kinney-Thomas E, Bruck C, Francotte M, Goudsmit J, Meloen RH.

Arch Virol. 1992;126(1-4):129-46.

PMID:
1381908
28.

Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.

Langedijk JP, Back NK, Durda PJ, Goudsmit J, Meloen RH.

J Gen Virol. 1991 Oct;72 ( Pt 10):2519-26.

PMID:
1919529
29.
30.

Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope.

Back NK, Haigwood NL, de Wolf F, de Jongh BM, Goudsmit J.

Intervirology. 1991;32(3):160-72.

PMID:
2040587
31.

Association of antibodies blocking HIV-1 gp 160-sCD4 attachment with virus neutralizing activity in human sera.

Back NK, Thiriart C, Delers A, Ramautarsing C, Bruck C, Goudsmit J.

J Med Virol. 1990 Jul;31(3):200-8.

PMID:
1697332

Supplemental Content

Support Center